The ultimate resource on the IRA
On August 16, 2022, President Joe Biden signed the Inflation Reduction Act (IRA) into law. Significant changes are coming regarding drug pricing and payment in the United States.
There are a number of implications that biopharma companies will need to consider across the full drug discovery, development, and commercialization spectrum as they adapt to this U.S. marketplace reality.
Explore our insights and perspectives on the key elements of the new law and tap into our comprehensive understanding of the IRA. Contact us to start a conversation and our health policy and government affairs experts can guide you to the right solutions to help you navigate the IRA.
Cencora PayerPulse:
The unintended consequences of the Inflation Reduction Act (IRA)
Diagnosing the health (policy) of our nation: The impact of November’s elections
As the US November general election results unfold, healthcare stakeholders are keen to understand their implications for federal health policy. This article highlights key takeaways on how the evolving political landscape will impact market access, regulatory priorities, and patient outcomes, offering strategies to prepare for these changes.
Panel discussion: Strategically prepare for IRA Part D redesign
Experts from the Cencora reimbursement and policy insights team hosted an engaging panel discussion for a deep five into action plan around the implications of IRA, and to address questions from the audience on determining patient assistance programs eligibility criteria, communication strategies, education and outreach.
Connect with one of our experts
Pardot Form
Prepare your patient support program for IRA’s impact
The Part D benefit redesign — as part of the Inflation Reduction Act (IRA) — is almost here. Are you doing enough to prepare your patient support program for it? Watch the video as Corey Ford, Cencora’s VP of Reimbursement and Policy Insights gives a brief overview of what you need to know.
Inflation Reduction Act Insights
First 10 drugs for Medicare price negotiation announced under IRA
For the first time in history, Medicare will directly negotiate a maximum fair price of select high expenditure, single source drugs without a generic or biosimilar equivalent. Read more to see the 10 drugs include the price negotiations.
Available on-demand webinar: IRA Update: Key considerations for 2023
Don't miss out on this valuable opportunity to learn about key dates, the implementation timeline, and the potential impacts the Inflation Reduction Act (IRA) will have on the biopharma industry. Download the webinar to learn more.
Policy updates: From the Inflation Reduction Act to the Enhancing Oncology Model
Cencora’s U.S. Policy and Advocacy team provides a summary of the newly passed Inflation Reduction Act of 2022, and Christopher Brunner, Senior Regional Manager of Oncology Supply at Cencora, walks us through the upcoming Enhancing Oncology Model and steps practices can take to ensure a strong start in 2023.
How will the Inflation Reduction Act affect the biopharma industry?
The Inflation Reduction Act (IRA) of 2022 will have a substantial impact on biopharma companies. It is the most significant healthcare legislation since the Affordable Care Act (ACA) in 2010. The biopharma industry should be aware that the IRA will affect drug pricing, reimbursement strategies, and patient assistance program designs.